ACETYLCYSTEINE

Post-LOE

acetylcysteine

ANDAINHALATION, ORALSOLUTION
Approved
Aug 1994
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
18

Mechanism of Action

Reduction Activity

Pharmacologic Class:

Antidote

Indications (1)

Clinical Trials (5)

NCT05070650Phase 3Withdrawn

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Started Sep 2024
NCT05241262Phase 1Recruiting

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

Started Jul 2023
18 enrolled
Mitochondrial Disease
NCT04481048Phase 2Active Not Recruiting

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

Started Dec 2020
58 enrolled
Neurofibromatosis 1
NCT04419025Phase 2Completed

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Started Sep 2020
165 enrolled
COVIDSars-CoV2SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere+1 more
NCT02791945Phase 2Completed

N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI

Started Aug 2016
30 enrolled
Traumatic Brain Injury (TBI)Hazardous and Harmful Alcohol Use